Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Malignant Chest Wall Neoplasm|Recurrent Breast Carcinoma|Recurrent Inflammatory Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Inflammatory Breast Carcinoma
Interventions: OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Talimogene Laherparepvec
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)